Salmonella-specific monoclonal antibodies against recombinant Salmonella typhi 36-kilodalton porin

Kissel, Vincent; González, Carlos; Astudillo, Michael; Godard, Anne; Wachman, B; Cabello, Felipe C.

doi:10.1128/cdli.1.2.250-252.1994

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such a strategy will permit production of a vaccine with adequate stability in the aggressive environment of the intestinal tract and the ability to bind M cells to favor induction of the most effective immune responses. The combination with other treatments, including passive delivery of specific monoclonal antibodies (236), DNA vaccination (237) or recombinant probiotic delivery, may turn out to eventually define the optimal system to fight the still-devastating consequences of Salmonella infection worldwide.…”

Section: Resultsmentioning

confidence: 99%

Vaccination against Salmonella Infection: the Mucosal Way

Gayet¹,

Bioley²,

Rochereau³

et al. 2017

Microbiol Mol Biol Rev

View full text Add to dashboard Cite

subspecies includes several serovars infecting both humans and other animals and leading to typhoid fever or gastroenteritis. The high prevalence of associated morbidity and mortality, together with an increased emergence of multidrug-resistant strains, is a current global health issue that has prompted the development of vaccination strategies that confer protection against most serovars. Currently available systemic vaccine approaches have major limitations, including a reduced effectiveness in young children and a lack of cross-protection among different strains. Having studied host-pathogen interactions, microbiologists and immunologists argue in favor of topical gastrointestinal administration for improvement in vaccine efficacy. Here, recent advances in this field are summarized, including mechanisms of bacterial uptake at the intestinal epithelium, the assessment of protective host immunity, and improved animal models that closely mimic infection in humans. The pros and cons of existing vaccines are presented, along with recent progress made with novel formulations. Finally, new candidate antigens and their relevance in the refined design of anti- vaccines are discussed, along with antigen vectorization strategies such as nanoparticles or secretory immunoglobulins, with a focus on potentiating mucosal vaccine efficacy.

show abstract

Section: Resultsmentioning

confidence: 99%